Aitia

Aitia is a pioneer in utilizing Causal AI and Digital Twins for drug discovery. By leveraging multi-omic patient data, high-performance computing, causal learning, and AI, Aitia uncovers hidden biological disease mechanisms to create Digital Twins for oncology, neurodegenerative disorders, and immunology. Their Gemini Digital Twins play a pivotal role in identifying new therapies and accelerating R&D for diseases such as multiple myeloma, prostate cancer, Alzheimer’s, Parkinson’s, and Huntington’s. Aitia has collaborations with seven of the top ten pharmaceutical companies, leading academic research centers, medical societies, multi-omic data companies, and global patient advocacy groups.

Founded in 2000, Aitia operates in the Big Data industry. Their most recent funding round was a $23.00M Series D investment on 09 July 2019, with participation from notable investors including Amgen Ventures, Alexandria Venture Investments, Celgene, Cigna Ventures, Echo Health Ventures, and Gary Loveman.